|
|
||||||||
The Journal of Thoracic and Cardiovascular Surgery, Vol 96, 652-666, Copyright © 1988 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association
WR Jamieson, AI Munro, RT Miyagishima, LH Burr, AN Gerein, MT Janusz, GF Tyers and P Allen
The Carpentier-Edwards supraannular porcine bioprosthesis, an
investigational valve, was implanted in 1167 patients (1174 operations,
1274 valves) between November 1981 and December 1985 (age range 13 to 85
years, mean 61 years). The early mortality rate was 7.2% (with concomitant
procedures 10.9%, without 4.8%; with previous operation 10.5%, without
6.6%). The late mortality rate was 4.5% per patient-year (aortic valve
replacement, 4.0%; mitral valve replacement, 4.8%; multiple valve
replacement, 5.6%). Total cumulative follow-up was 2272.3 years. The
prevalence of thromboembolism was 2.6% per patient- year (fatal 0.4% per
patient-year, major 1.4%, minor 1.2%); hemorrhage related to
antithromboembolic therapy, 0.7% (fatal 0.1%); prosthetic valve
endocarditis, 0.4% (fatal 0.2%); periprosthetic leak, 0.4% (fatal 0%);
structural valve deterioration (primary tissue failure/structural failure),
0.1% per patient-year; and clinical valve dysfunction, 0.4%. The
reoperation rate was 0.8% per patient-year (thromboembolism, 0.1%; clinical
valve dysfunction, 0.1%; prosthetic valve endocarditis, 0.1%;
periprosthetic leak, 0.4%; structural valve deterioration, 0.1%).
Thromboembolism occurred throughout the observation period but with
decreasing frequency, hemorrhage throughout the period in no predictable
fashion, prosthetic valve endocarditis within 2 years, periprosthetic leak
within 2 years, and structural valve deterioration occurred during the
fourth year of assessment. The overall survival rate was 79.8% +/- 1.7% (4
years). Freedom (at 4 years) from thromboembolism was 92.2% +/- 1.2%; from
structural valve deterioration, 98.8% +/- 0.8%; and from reoperation, 95.8%
+/- 1.3%. Freedom from all complications (4 years) was 85.9% +/- 1.7%; from
complication mortality, 98.4% +/- 0.4%; and from valve failure (mortality
and reoperation), 94.3% +/- 1.3%. This investigational Carpentier-Edwards
supraannular porcine bioprosthetic valve has provided excellent clinical
performance and remains our overall prosthesis of choice.
ARTICLES
The Carpentier-Edwards supraannular porcine bioprosthesis. A new generation tissue valve with excellent intermediate clinical performance
University of British Columbia, Vancouver, Canada.
This article has been cited by other articles:
![]() |
N. D. Desai and G. T. Christakis Bioprosthetic Aortic Valve Replacement: Stented Pericardial and Porcine Valves Card. Surg. Adult, January 1, 2008; 3(2008): 857 - 894. [Full Text] |
||||
![]() |
N. D. Desai and G. T. Christakis Stented Mechanical/Bioprosthetic Aortic Valve Replacement Card. Surg. Adult, January 1, 2003; 2(2003): 825 - 856. [Full Text] |
||||
![]() |
B. Yamak, M. Emir, T. A Ulus, A. Aksoyek, Z. Iscan, S F. Katircioglu, O. Tasdemir, B. Yamak, M. Emir, T. A Ulus, et al. Pregnancy With St. Jude Medical Mitral Valve Prosthesis Asian Cardiovasc Thorac Ann, June 1, 2000; 8(2): 127 - 129. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Kallis, J. F. Sneddon, I. A. Simpson, A. Fung, J. R. Pepper, and E. E. John Smith Clinical and hemodynamic evaluation of the 19-mm Carpentier-Edwards supraannular aortic valve Ann. Thorac. Surg., December 1, 1992; 54(6): 1182 - 1185. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |